Anthropic, the AI company behind Claude chatbot, just bought a mysterious biotech startup called Coefficient Bio for $400 million in stock. The startup was operating in “stealth mode,” meaning almost nobody knew what they were working on.
This is Anthropic’s biggest move yet into applying AI beyond chatbots. While most people know Anthropic for competing with ChatGPT, they’re now betting big that AI can revolutionize medicine and biology.
The Secret Biotech Lab
Coefficient Bio has been working quietly on using AI to understand biological processes, though details about their specific projects remain unclear. Stealth startups like this typically spend years developing technology before revealing what they’re building.
The $400 million price tag shows how seriously Anthropic takes the opportunity. That’s massive money for a company most people have never heard of. But it makes sense when you consider that AI could help discover new medicines, understand diseases better, or even design new treatments.
Anthropie isn’t alone in this space. Google’s DeepMind famously used AI to predict protein structures, solving a 50-year-old science problem. Microsoft has partnered with pharmaceutical companies to speed up drug discovery using AI.
What’s Next
Expect to see Anthropic announce new AI tools for scientists and researchers in the coming months. The biotech industry moves slowly, so real breakthroughs might take years. But this acquisition signals that AI companies see biology as the next big frontier after mastering language and conversation.